Primarily used in the treatment of non-small cell lung cancer (NSCLC), it functions as a triple angiokinase inhibitor, targeting key receptors involved in tumor growth and blood vessel formation. It is often administered in combination with other chemotherapy agents to enhance therapeutic outcomes. Additionally, it has shown potential in reducing tumor progression and improving patient survival rates. Clinical trials have also explored its efficacy in other cancers, such as ovarian and colorectal cancer, though its use in these areas remains under investigation. It is typically prescribed for patients who have not responded well to other treatments, offering an alternative option for managing advanced stages of the disease.